Clinigen Group plc Extended partnership agreement signed with BMS
31 May 2018 - 4:00PM
RNS Non-Regulatory
TIDMCLIN
Clinigen Group plc
31 May 2018
RNS Reach
31 May 2018
Clinigen and Bristol-Myers Squibb sign extended partnership
agreement in South Africa
Clinigen Group plc (AIM: CLIN, 'Clinigen' or the 'Group'), the
global pharmaceutical and services company, has signed a commercial
agreement with Bristol-Myers Squibb ('BMS') in South Africa. The
agreement covers BMS' South African portfolio of products for an
initial period of five years.
Clinigen's Commercial Medicines business operation will provide
access for patients in South Africa for the BMS products. Clinigen
will provide local regulatory expertise, supply and distribution
infrastructure and experience in managing licensed medicines in the
region. The agreement will lead to the transfer of Marketing
Authorisations (product registration certificates) from BMS to
Clinigen, which will likely be completed in the first half of
2019.
In the Africa and Asia Pacific region, Clinigen has 192 actively
marketed specialist pharmaceutical and medical technology licensed
products, including both branded and generic products. This
agreement with Bristol-Myers Squibb will complement the Group's
growing basket of essential medicine on offer to healthcare
providers and their patients in the region.
Shaun Chilton, Group Chief Executive Officer, Clinigen,
said:
"This agreement demonstrates the long and successful
relationship we have built with BMS, which began with providing
access to BMS' unlicensed products globally, and has grown with
Clinigen's expansion into important future growth markets.
"Clinigen is increasingly becoming the partner of choice for
pharmaceutical companies to license and distribute their products.
This agreement shows that our strategy for Commercial Medicines of
adding regional commercial agreements to our existing portfolio of
global products, a key strategic priority for the Group, is
working."
- Ends -
Contact details
Clinigen Group plc Tel: +44 (0) 1283
495010
Shaun Chilton, Group Chief
Executive Officer
Matt Parrish, Head of Investor
Relations
Numis Securities Limited Tel: +44 (0) 20 7260
1000
Michael Meade / Freddie Barnfield
(Nominated Adviser)
James Black / Tom Ballard
(Corporate Broking)
RBC Capital Markets - Joint Tel: +44 (0) 20 7653
Broker 4000
Marcus Jackson / Elliot Thomas
Instinctif Partners Tel: +44 (0) 20 7457
2020
Melanie Toyne-Sewell / Alex Email: clinigen@instinctif.com
Shaw / Deborah Bell
Notes to Editors
About Clinigen Group
Clinigen Group plc (AIM: CLIN) is a global pharmaceutical and
services company with a unique combination of businesses focused on
providing ethical access to medicines. Its mission is to deliver
the right medicine to the right patient at the right time through
three areas of global medicine supply; clinical trial, unlicensed
and licensed medicines.
Clinical Trial Services
Clinigen is the global market leader in the specialist supply
and management of quality-assured comparator medicines and services
to clinical trials and Investigator Initiated Trials.
Unlicensed Medicines
Clinigen is the global leader in ethically sourcing and
supplying unlicensed medicines to hospital pharmacists and
physicians for patients with a high unmet medical need. The Group
manages early access programmes to innovative new medicines and
provides 'on demand' access globally to medicines which remain
unlicensed at the point of care.
Commercial Medicines
Clinigen acquires global rights to niche hospital only and
critical care products, revitalising these assets around the world
and returning them back to sustained growth. It also provides
access to licensed and branded generic medicines in the Africa and
Asia Pacific region.
The Group also has an 'unlicensed to licensed' strategy, where
it looks to take unlicensed medicines with commercial potential and
licence them, helping to address unmet medical need and allowing
the Group to capitalise on its market-leading positions.
For more information on Clinigen, please visit
www.clinigengroup.com
About Bristol-Myers Squibb
Bristol-Myers Squibb is a global biopharmaceutical company whose
mission is to discover, develop and deliver innovative medicines
that help patients prevail over serious diseases. For more
information about Bristol-Myers Squibb, visit us at BMS.com or
follow us on LinkedIn, Twitter, YouTube and Facebook.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NRALLFSEEEIIVIT
(END) Dow Jones Newswires
May 31, 2018 02:00 ET (06:00 GMT)
Clinigen (LSE:CLIN)
Historical Stock Chart
From Apr 2024 to May 2024
Clinigen (LSE:CLIN)
Historical Stock Chart
From May 2023 to May 2024